Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics
Amount Raised
$30 Million
Round Type
Series A
HaywardBiotechnologyHealthcareDescription
Spotlight Therapeutics, Inc., a biotechnology company developing non-viral gene editing therapeutics for direct in vivo editing of target genes, closed its Series A financing bringing the total raised to $30 million. The financing was led by GV, formerly Google Ventures, with participation from additional undisclosed investors.
Who to call at Spotlight Therapeutics, Inc., and when
A new round usually means Spotlight Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Spotlight Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Spotlight Therapeutics, Inc., from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Spotlight Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSpotlight Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.